Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
10 hedge funds and large institutions have $3.45M invested in Evoke Pharma in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
197% more capital invested
Capital invested by funds: $1.16M → $3.45M (+$2.29M)
43% more funds holding
Funds holding: 7 → 10 (+3)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.31M |
| 2 |
SC
Sophrosyne Capital
New York
|
+$485K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$101K |
| 5 |
Citigroup
New York
|
+$20K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$178K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$83K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$41.4K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$9.98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $1.96M | +$2.31M | +1,621 | New |
|
|
SC
2
Sophrosyne Capital
New York
| $411K | +$485K | +340 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $395K | +$110K | +77 | +31% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $281K | -$9.98K | -7 | -3% |
|
|
LP
5
LMR Partners
London,
United Kingdom
| $199K | +$237K | +166 | New |
|
|
TC
6
TFS Capital
West Chester,
Pennsylvania
| $88K | -$41.4K | -29 | -28% |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| $85K | +$101K | +71 | New |
|
|
8
Citigroup
New York
| $17K | +$20K | +14 | New |
|
|
U
9
UBS
Zurich,
Switzerland
| $11K | +$4.28K | +3 | +50% |
|
|
10
Morgan Stanley
New York
| $4K | -$178K | -125 | -98% |
|
|
ARTA
11
A.R.T. Advisors
New York
| – | -$83K | -78 | Closed |
|
EVOK Hedge Fund Activity: Q1 2014 in Review
10 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2014, worth a combined $3.45M — up 197% from $1.16M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVOK positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.31M. The largest seller was Morgan Stanley, cutting an estimated $178K.
- 10 institutional investors held Evoke Pharma (EVOK) as of Q1 2014, up from 7 in Q4 2013.
- Funds reported $3.45M of Evoke Pharma stock for Q1 2014, up 197% quarter-over-quarter.
- 5 funds opened new Evoke Pharma positions in Q1 2014 and 1 closed out, a net change of +4 holders.
- The largest Evoke Pharma buyer in Q1 2014 was Opaleye Management, an estimated $2.31M added.
- The largest Evoke Pharma seller in Q1 2014 was Morgan Stanley, an estimated $178K sold.
Based on aggregated 13F filings for Q1 2014.